Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083235 | 0.86 | GABRA1 (0.50) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL13265468 | 0.79 | GABRA1 (0.44) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL320332 | 0.79 | ALDH1A1 (0.64) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL15653839 | 0.79 | ALDH1A1 (0.64) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL8791921 | 0.78 | GABRA1 (0.43) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL166586 | 0.78 | GABRA1 (0.52) | ALDH1A1MEN1KMT2AMAPTGABRA1 | |
| SCHEMBL5454241 | 0.77 | GABRA1 (0.43) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL5227993 | 0.77 | GABRA1 (0.43) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL15654024 | 0.77 | ALDH1A1 (0.61) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL8262686 | 0.77 | ALDH1A1 (0.61) | ALDH1A1TDP1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197393-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES | WITSCHEL MATTHIAS | 2007-08-23 | — | — | US | disclosed |
| EP-1163240-B1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES USED AS A HERBICIDE | BASF AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-7115545-B1 | Tricyclic benzoylpyrazole derivatives used as a herbicide | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| EP-1181295-B1 | TRICYCLIC BENZOYLCYCLOHEXANEDIONE DERIVATIVES | BASF AG (DE) | 2004-02-18 | — | — | EP | disclosed |
| US-6583089-B1 | Pre- and postemergence herbicides such as (5,5-dimethyl-1,3-dioxocyclohex-2yl)(6-methoxy-3a,4-dihydro-3H -chromeno(4,3c) isoxazolin-9-yl)methanone, formed by acylation and rearranging in the presence of catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-24 | — | — | US | disclosed |
| CN-1358186-A | Tricyclic benzoylcylohexanedione derivatives | BASF AG (DE) | 2002-07-10 | — | — | CN | disclosed |
| EP-1181295-A2 | TRICYCLIC BENZOYLCYCLOHEXANEDIONE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | disclosed |
| EP-1163240-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES USED AS A HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000073311-A2 | TRICYCLIC BENZOYLCYCLOHEXANEDIONE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000055158-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES USED AS A HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197393-A1 | TRICYCLIC BENZOYLPYRAZOLE DERIVATIVES | CBR3, CBR1, KAT8 | ALDH1A1 4069/4885TDP1 3614/4885MEN1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.